BIOVF News and Press, Swedish Orphan Biovit Ord From 04/27/23

2023-04-27 12:54:50 ET Swedish Orphan Biovitrum AB press release ( OTCPK:BIOVF ): Q1 Non-GAAP EPS of SEK3.60. Revenue of SEK5.24M. For further details see: Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK3.60, revenue of SEK5.24M

Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A: Swedish Orphan Biovitrum AB PR Newswire Primary endpoint was met with no factor VIII inhibitors detected, confirming the safety profile ...

AstraZeneca ( NASDAQ: AZN ) and Sanofi's ( NASDAQ: SNY ) antibody therapy Beyfortus continues to show consistent protection against Respiratory Syncytial Virus (RSV) disease through the RSV season in infants, the British drugmaker said on Tuesday. AstraZeneca said it will...

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2022 Results Conference Call February 08, 2023 07:00 AM ET Company Participants Guido Oelkers - CEO Henrik Stenqvist - CFO Anders Ullman - Head of R&D Conference Call Participants Christopher Uhde - SEB ...

Swedish Orphan Biovitrum AB press release ( OTCPK:BIOVF ): Q4 GAAP EPS of SEK 4.68. Revenue of SEK 5.99B (+22.2% Y/Y). EBITA SEK 2,455M; EBITA margin 41%. EBIT SEK 1,916M. Outlook 2023: Revenue is anticipated to grow by a low-to-mid single-digit p...

Swedish Orphan Biovitrum AB ( OTCPK:BIOVF ), the biotech also known as Sobi, has received the FDA’s Emergency Use Authorization (EUA) for its anti-inflammatory medication Kineret as a treatment for certain hospitalized patients with COVID-19. The FDA decision was backed...

The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2022 Q3 earnings call. For further details see: Swedish Orphan Biovitrum AB (publ) 2022 Q3 - Results - Earnings Call Presentation

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2022 Earnings Conference Call October 27, 2022 07:00 ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Financial Officer Anders Ullman - Head R&D and Medical Affairs and Chie...

Swedish Orphan Biovitrum AB press release ( OTCPK:BIOVF ): Q3 GAAP EPS of SEK 1.52. Revenue of SEK 4B (+6.4% Y/Y). EBITA of SEK 1,241M; EBITA margin of 31%. EBIT of SEK 699M. Cash flow from operating activities SEK 780M. 2022 outlo...

Swedish Orphan Biovitrum AB (BIOVF) Q2 2022 Earnings Conference Call July 19, 2022 07:00 AM ET Company Participants Guido Oelkers - CEO Henrik Stenqvist - CFO Anders Ullman - Head, R&D and CMO Armin Reininger - Head of Medical and Scientific Affairs ...